Bioxytran (BIXT) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Bioxytran (BIXT) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.25% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.44% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 62.15% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 24.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.25% |
| Dec 31, 2025 | 15.52% |
| Sep 30, 2025 | -11.65% |
| Jun 30, 2025 | 27.15% |
| Mar 31, 2025 | -14.06% |
| Dec 31, 2024 | 10.19% |
| Sep 30, 2024 | 6.18% |
| Jun 30, 2024 | 9.64% |
| Mar 31, 2024 | 29.27% |
| Dec 31, 2023 | -13.04% |
| Sep 30, 2023 | -77.38% |
| Jun 30, 2023 | -15.96% |
| Mar 31, 2023 | -14.81% |
| Dec 31, 2022 | -9.33% |
| Sep 30, 2022 | 38.52% |
| Jun 30, 2022 | -69.46% |
| Mar 31, 2022 | -68.29% |
| Dec 31, 2021 | -61.18% |
| Sep 30, 2021 | -115.43% |
| Jun 30, 2021 | -1,382.88% |